EPO and hypertensive disorder: Using a nitric oxide synthase inhibitor to recreate hypertension in a rat hypertension model, administration of oral recombinant human EPO reduced NOX-dependent O2•- production, enhanced the expression of suppressor cytokine signaling-1, and improved vasodilation [113].